SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sagimet Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.86+0.84 (+10.47%)
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.50 (+20.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $470.59M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.84
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$47.08M
- EPS, diluted
- -$1.28
- Book value per share
- $4.82
- Diluted shares
- 53M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$52.63M
Net income
-$47.08M
EPS, diluted
-$1.28
Reported periodTrailing twelve months